However, combined treatment with trastuzumab and FAP-IL2v induced a pronounced anti-cancer response compared to control regimens (Fig. 5f), thus suggesting a prominent role of NK cells in driving trastuzumab/FAP-IL2v treatment efficiency. This evidence concerns the gene FAP and cancer.